224 related articles for article (PubMed ID: 20190467)
41. Maximal dose-response of vitamin-K2 (menaquinone-4) on undercarboxylated osteocalcin in women with osteoporosis.
K Giri T; Newton D; Chaudhary O; Deych E; Napoli N; Villareal R; Diemer K; E Milligan P; F Gage B
Int J Vitam Nutr Res; 2020 Jan; 90(1-2):42-48. PubMed ID: 30816822
[No Abstract] [Full Text] [Related]
42. Reducing Undercarboxylated Osteocalcin With Vitamin K Supplementation Does Not Promote Lean Tissue Loss or Fat Gain Over 3 Years in Older Women and Men: A Randomized Controlled Trial.
Shea MK; Dawson-Hughes B; Gundberg CM; Booth SL
J Bone Miner Res; 2017 Feb; 32(2):243-249. PubMed ID: 27604070
[TBL] [Abstract][Full Text] [Related]
43. Between-meal risedronate does not alter bone turnover in nursing home residents.
Agrawal S; Krueger DC; Engelke JA; Nest LJ; Krause PF; Drinka PJ; Binkley NC
J Am Geriatr Soc; 2006 May; 54(5):790-5. PubMed ID: 16696745
[TBL] [Abstract][Full Text] [Related]
44. Diet- or warfarin-induced vitamin K insufficiency elevates circulating undercarboxylated osteocalcin without altering skeletal status in growing female rats.
Haffa A; Krueger D; Bruner J; Engelke J; Gundberg C; Akhter M; Binkley N
J Bone Miner Res; 2000 May; 15(5):872-8. PubMed ID: 10804016
[TBL] [Abstract][Full Text] [Related]
45. Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women.
Lai PS; Chua SS; Chew YY; Chan SP
J Clin Pharm Ther; 2011 Oct; 36(5):557-67. PubMed ID: 21916908
[TBL] [Abstract][Full Text] [Related]
46. Prior treatment with vitamin K(2) significantly improves the efficacy of risedronate.
Matsumoto Y; Mikuni-Takagaki Y; Kozai Y; Miyagawa K; Naruse K; Wakao H; Kawamata R; Kashima I; Sakurai T
Osteoporos Int; 2009 Nov; 20(11):1863-72. PubMed ID: 19280272
[TBL] [Abstract][Full Text] [Related]
47. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients.
Dobnig H; Hofbauer LC; Viereck V; Obermayer-Pietsch B; Fahrleitner-Pammer A
Osteoporos Int; 2006; 17(5):693-703. PubMed ID: 16435076
[TBL] [Abstract][Full Text] [Related]
48. Modulation of bone turnover in orchidectomized rats treated with raloxifene and risedronate.
Khedr NF; El-Ashmawy NE; El-Bahrawy HA; Haggag AA; El-Abd EE
Fundam Clin Pharmacol; 2013 Oct; 27(5):526-34. PubMed ID: 22762129
[TBL] [Abstract][Full Text] [Related]
49. Increased undercarboxylated osteocalcin/intact osteocalcin ratio in patients undergoing hemodialysis.
Nagata Y; Inaba M; Imanishi Y; Okazaki H; Yamada S; Mori K; Shoji S; Koyama H; Okuno S
Osteoporos Int; 2015 Mar; 26(3):1053-61. PubMed ID: 25403902
[TBL] [Abstract][Full Text] [Related]
50. Effect of GGCX gene polymorphism on the responses of serum undercarboxylated osteocalcin and bone turnover markers after treatment with vitamin K2 (menatetrenone) among postmenopausal Thai women.
Songpatanasilp T; Chailurkit LO; Chantprasertyothin S; Ongphiphadhanakul B; Taechakraichana N
J Bone Miner Metab; 2011 Sep; 29(5):606-14. PubMed ID: 21344298
[TBL] [Abstract][Full Text] [Related]
51. Vitamin K, bone turnover, and bone mass in girls.
Kalkwarf HJ; Khoury JC; Bean J; Elliot JG
Am J Clin Nutr; 2004 Oct; 80(4):1075-80. PubMed ID: 15447922
[TBL] [Abstract][Full Text] [Related]
52. Oral risedronate sodium improves bone mineral density in non-ambulatory patients: a randomized, double-blind, placebo controlled trial.
Cohran V; Cassedy A; Hawkins A; Bean J; Heubi J
J Pediatr Rehabil Med; 2013; 6(2):85-93. PubMed ID: 23803341
[TBL] [Abstract][Full Text] [Related]
53. Clinical efficacy of oral risedronate therapy in Japanese patients with Paget's disease of bone.
Ohara M; Imanishi Y; Nagata Y; Ishii A; Kobayashi I; Mori K; Ito M; Miki T; Nishizawa Y; Inaba M
J Bone Miner Metab; 2015 Sep; 33(5):584-90. PubMed ID: 25319558
[TBL] [Abstract][Full Text] [Related]
54. Effects of vitamin K in postmenopausal women: mini review.
Guralp O; Erel CT
Maturitas; 2014 Mar; 77(3):294-9. PubMed ID: 24342502
[TBL] [Abstract][Full Text] [Related]
55. Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation.
van Bodegraven AA; Bravenboer N; Witte BI; Dijkstra G; van der Woude CJ; Stokkers PC; Russel MG; Oldenburg B; Pierik M; Roos JC; van Hogezand RA; Dik VK; Oostlander AE; Netelenbos JC; van de Langerijt L; Hommes DW; Lips P;
Gut; 2014 Sep; 63(9):1424-30. PubMed ID: 24146170
[TBL] [Abstract][Full Text] [Related]
56. An Increased Serum N-Terminal Telopeptide of Type I Collagen, a Biochemical Marker of Increased Bone Resorption, Is Associated with Infliximab Therapy in Patients with Crohn's Disease.
Sugimoto K; Ikeya K; Iida T; Kawasaki S; Arai O; Umehara K; Watanabe F; Tani S; Oishi S; Osawa S; Yamamoto T; Hanai H
Dig Dis Sci; 2016 Jan; 61(1):99-106. PubMed ID: 26254083
[TBL] [Abstract][Full Text] [Related]
57. Age-related changes in serum undercarboxylated osteocalcin and its relationships with bone density, bone quality, and hip fracture.
Liu G; Peacock M
Calcif Tissue Int; 1998 Apr; 62(4):286-9. PubMed ID: 9504950
[TBL] [Abstract][Full Text] [Related]
58. Decreased Levels of Circulating Carboxylated Osteocalcin in Children with Low Energy Fractures: A Pilot Study.
Popko J; Karpiński M; Chojnowska S; Maresz K; Milewski R; Badmaev V; Schurgers LJ
Nutrients; 2018 Jun; 10(6):. PubMed ID: 29882816
[TBL] [Abstract][Full Text] [Related]
59. Effectiveness of vitamin K2 on osteoporosis in adults with cerebral palsy.
Kodama Y; Okamoto Y; Kubota T; Hiroyama Y; Fukami H; Matsushita K; Kawano Y
Brain Dev; 2017 Nov; 39(10):846-850. PubMed ID: 28624135
[TBL] [Abstract][Full Text] [Related]
60. Treatment with tiludronate has a similar effect to risedronate on Paget's disease activity assessed by bone markers and bone scintigraphy.
Peris P; Alvarez L; Vidal S; Martínez MA; Monegal A; Guañabens N
Clin Exp Rheumatol; 2007; 25(2):206-10. PubMed ID: 17543143
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
